Atacand (Candesartan) Real Life Study

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00620178
First received: February 8, 2008
Last updated: December 1, 2010
Last verified: December 2010
  Purpose

This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)


Condition Intervention
Hypertension
Drug: Candesartan Cilexetil
Drug: Losartan

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD). [ Time Frame: 1999 - 2007 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new [ Time Frame: 1999 - 2007 ] [ Designated as safety issue: No ]
  • Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward). [ Time Frame: 1999 - 2007 ] [ Designated as safety issue: No ]

Estimated Enrollment: 14000
Study Start Date: March 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Candesartan
Drug: Candesartan Cilexetil
oral once daily dose
Other Name: ATACAND
2
Losartan
Drug: Losartan
once daily oral dose
Other Name: COZAAR

  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Eligible subjects are all patients found in EPS systems at the participating centres, who were prescribed candesartan (ATC-C09CA06) or losartan (C09CA01) for hypertension from 1 January 1999 - 31 December 2004 inclusive. The first found prescription is designated as index.

Criteria

Inclusion Criteria:

  • Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
  • Diagnosed as hypertensive within 15 months
  • First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive

Exclusion Criteria:

  • Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00620178

Locations
Sweden
Research Site
Uppsala, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Jan Stålhammar, MD Eriksbergs vårdcentral
  More Information

No publications provided

Responsible Party: Anders Ljunggren, MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00620178     History of Changes
Other Study ID Numbers: NIS-CSE-ATA-2008/1
Study First Received: February 8, 2008
Last Updated: December 1, 2010
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by AstraZeneca:
candesartan
losartan
blood pressure
cardiovascular disease
health care consumption

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Losartan
Candesartan cilexetil
Candesartan
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 19, 2014